We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Data published from UK’s independent medicines regulator confirms approved vaccines meet strict regulatory standards for safety
The study will examine whether different vaccines can safely be used for 2-dose regimes in the future.
First published during the 2019 to 2022 Johnson Conservative government
Significant milestone reached as almost 1 in 5 adults in the UK get the vaccine.
Deal takes total number of Valneva vaccines to 100 million, to be manufactured in the UK in Scotland
Janssen today published positive data from the Phase 3 studies of its single-dose COVID-19 vaccine candidate, showing it to be 66% effective overall in preventing coronavirus in participants.
Novavax today published positive data from the UK phase 3 study of its COVID-19 vaccine candidate, showing it to be 89.3% effective in preventing coronavirus in participants.
Findings from large-scale technical and clinical evaluation of LamPORE COVID-19 test confirm high sensitivity and specificity.
The Minister for Patient Safety, Suicide Prevention and Mental Health updates Parliament on the government’s response to the recommendations of the IMMDS Review.
The National Institute for Biological Standards and Control will carry out independent testing in the UK for any potential COVID-19 vaccines.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the Moderna vaccine after an extensive analysis of the vaccine’s safety, quality and effectiveness.
The vaccine has been approved after meeting the required safety, quality and effectiveness standards.
The Access Consortium regulatory authorities have pledged our collective support in countering the COVID-19 global pandemic.
The first people will receive the Oxford University/AstraZeneca coronavirus vaccine today (4 January 2021) as the NHS rapidly expands COVID-19 vaccination programmes across the UK.
Women receiving treatment for epilepsy are being urged to discuss with a healthcare professional the right treatment for them if they anticipate becoming pregnant even sometime in the future, following a safety review.
The Medicines and Healthcare products Regulatory Agency (MHRA) today, 1 January 2021, formally starts the Innovative Licensing and Access Pathway (ILAP).
Oxford University/AstraZeneca vaccine meets regulator’s strict standards of safety, efficacy and quality.
The Joint Committee on Vaccination and Immunisation (JCVI) has issued its advice on the AstraZeneca COVID-19 vaccine.
The new vaccine has been approved after meeting the required safety, quality and effectiveness standards.
Joint clinical advice from the 4 UK Chief Medical Officers on the prioritisation of first doses of the coronavirus (COVID-19) vaccines.
Government update on the Oxford University/AstraZeneca COVID-19 vaccine.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).